Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.8880
+0.0019 (0.21%)
At close: Oct 8, 2025, 4:00 PM EDT
0.9000
+0.0120 (1.35%)
After-hours: Oct 8, 2025, 5:24 PM EDT
Assertio Holdings Revenue
Assertio Holdings had revenue of $29.22M in the quarter ending June 30, 2025, a decrease of -6.12%. This brings the company's revenue in the last twelve months to $117.10M, down -11.41% year-over-year. In the year 2024, Assertio Holdings had annual revenue of $124.96M, down -17.83%.
Revenue (ttm)
$117.10M
Revenue Growth
-11.41%
P/S Ratio
0.72
Revenue / Employee
$2,018,948
Employees
58
Market Cap
85.46M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 124.96M | -27.11M | -17.83% |
Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
Dec 31, 2021 | 111.01M | 2.94M | 2.72% |
Dec 31, 2020 | 108.08M | -121.45M | -52.91% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ASRT News
- 20 days ago - DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025 - GlobeNewsWire
- 23 days ago - Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV - GlobeNewsWire
- 4 weeks ago - Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association - GlobeNewsWire
- 5 weeks ago - Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 - GlobeNewsWire
- 2 months ago - Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Assertio Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors - PRNewsWire
- 2 months ago - Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 - GlobeNewsWire